Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Revolymer was a UK-listed specialty polymer company that developed proprietary functional polymers for consumer, industrial, and healthcare applications, including low-adhesion chewing gum and nicotine replacement gum products. Although it had some healthcare exposure through nicotine gum, the company was not a therapeutics-focused biotech or pharma developer; its core competency was polymer formulation, controlled-release systems, and specialty materials. In 2016, Revolymer acquired Itaconix Corporation and simultaneously divested its nicotine gum business to Alkalon as part of a strategic refocus. In February 2017, the company changed its name from Revolymer plc to Itaconix plc, and its UK operating subsidiary was renamed Itaconix (U.K.) Limited. As a result, Revolymer no longer exists as an active standalone company name, but survives historically as the predecessor identity of Itaconix.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Revolymer.